Introduction {#S0001}
============

Community-acquired pneumonia (CAP) is a common infection. Despite substantial progress in therapeutic options, the mortality remains unacceptably high \[[@CIT0001]\], as high as 58% in patients with severe CAP admitted to the intensive care unit \[[@CIT0002]\]. *Mycoplasma pneumoniae* is an important causative organism of CAP, accounting for 10--30% of all cases \[[@CIT0003]--[@CIT0005]\]. The frequency of CAP due to *M. pneumoniae* was 20.7% in China from December 2003 to November 2004 \[[@CIT0006]\]. Patients infected with *M. pneumoniae* constitute about 29% of ambulatory adult patients with CAP and about 20% of hospitalized low-risk CAP patients in China \[[@CIT0007], [@CIT0008]\]. Three--four percent of patients infected with *M. pneumoniae* are known to develop a severe life-threatening pneumonia with respiratory failure and acute respiratory distress syndrome \[[@CIT0009]\].

Although characteristic computed tomographic (CT) features of *M. pneumoniae* pneumonia have been described \[[@CIT0010]\], radiological findings are not particularly specific. The disease is most frequently characterized by bronchopneumonic or interstitial infiltrates usually in the lower lobe, unilaterally and centrally dense \[[@CIT0011]\].

Manifestations of infectious diseases may be influenced by both the pathogen and the host. In the case of *M. pneumoniae* pneumonia, mechanistic correlates of disease severity are poorly characterised. Generally, evidence from research on humans and animal models suggests that the immune system may on the one hand limit disease through the enhancement of host defence mechanisms but on the other hand exacerbate organ damage and systemic disease manifestations. Thus, the more vigorous the cell-mediated immune response and cytokine stimulation, the more severe the clinical illness and pulmonary injury \[[@CIT0004]\]. Consequently, it might be expected that radiological signs of pulmonary lesions in *M. pneumoniae* pneumonia might vary according to the demographics of the patients and clinical and laboratory findings. To our knowledge, however, these associations have so far been only partly addressed by a few studies \[[@CIT0010], [@CIT0012]--[@CIT0015]\].

In the present study, adult patients with CAP were selected to investigate the associations of radiological features with clinical and laboratory findings in a Chinese affiliated hospital.

Material and methods {#S0002}
====================

Design and setting {#S20003}
------------------

A retrospective cohort study was performed of 1230 adult patients who met the criteria for CAP presenting to the Department of Respiratory Medicine in a Chinese affiliated hospital of a medical college from 1^st^ January 2005 to 31^st^ December 2009, thus including five autumn-winter seasons.

Criteria for enrolment {#S20004}
----------------------

The CAP was defined as an acute infection of the pulmonary parenchyma associated with an acute infiltrate on the chest radiograph with two or more symptoms including fever (\> 38°C), hypothermia (\< 36°C), rigors, sweats, new cough or change in colour of respiratory secretions, chest discomfort or dyspnoea \[[@CIT0016]\].

Acute *M. pneumonia* infection was defined as a fourfold or greater increase in specific IgM and/or IgG titres between acute and convalescent phase serum samples. The CAP due only to acute *M. pneumonia* infection was defined as *M. pneumoniae* pneumonia. However, CAP caused by other pathogens and not having a fourfold or greater increase in specific IgM and/or IgG titres was defined as other pneumonias. Mixed pneumonia (atypical + bacteria) was discarded. Patients \< 18 years of age, any who had been hospitalized during the 28 days preceding the study, and any who had severe immunosuppression (e.g., patients with neutropenia after chemotherapy or bone marrow transplantation, patients with drug-induced immunosuppression as a result of solid-organ transplantation or corticosteroid or cytotoxic therapy, and patients with HIV-related disorders) \[[@CIT0017]\], active tuberculosis, or end-stage diseases, or who had a written "do not resuscitate" order were excluded. We also excluded patients with pulmonary emphysema, idiopathic interstitial pneumonia and malignant diseases. In such patients it is difficult to distinguish bronchopneumonia from lobar pneumonia and unifocal from multifocal disease. There were no patients with concurrent infectious disease.

We used recent definitions of radiological abnormalities as follows \[[@CIT0018]\]:

*Ground-glass opacity*: On chest radiographs, it appears as an area of hazy increased lung opacity, usually extensive, within which margins of pulmonary vessels may be indistinct. On CT scans, it appears as hazy increased opacity of lung, with preservation of bronchial and vascular margins.

*Consolidation*: It appears as a homogeneous increase in pulmonary parenchymal attenuation that obscures the margins of vessels and airway walls. An air bronchogram may be present.

Grouping {#S20005}
--------

One thousand two hundred and forty-five patients were selected and then 15 cases were excluded from this investigation due to exclusion criteria. A total of 1230 patients were accepted for the study. Three hundred and seventy-two patients with *M. pneumoniae*-associated pneumonia were included in one group and compared with 858 patients caused by infection due to other pathogens. Patients with ground-glass opacity were further designated as the bronchopneumonia subgroup and those with consolidation as the lobar pneumonia subgroup. Patients were also further subgrouped according to lobar involvement as follows: the unilobar opacity subgroup and the multilobar opacities subgroup ([Figure 1](#F0001){ref-type="fig"}).

![Study Flow Chart](AMS-10-23423-g001){#F0001}

Data collection {#S20006}
---------------

Clinical and diagnostic data and radiological features were collected from medical records following discharge. For the detection of *M. pneumoniae* specific IgM antibodies, the indirect microparticle agglutinin assay (Serodia-Myco II, Fujirebio, Japan, positive threshold value ≥ 1: 40) was used according to the manufacturer\'s instructions. *Mycoplasma pneumoniae* specific IgG antibodies were measured by SERION ELISA (enzyme-linked immunosorbent assay: Friedrich-Bergius-Ring 19, D-97076 Würzburg, Germany, positive threshold \> 30 U/ml). We analyzed *M. pneumoniae*-IgM titres as continuous variables after natural logarithmic transformation to normalize their distribution. CURB-65 (confusion, urea, respiratory rate, blood pressure, and age) scores at admission and sequential organ failure assessment (SOFA) scores at 72 h after commencing therapy were calculated. We also recorded total hospital costs, including pharmacy, radiology, and laboratory costs (including tests of blood, urine and stool, arterial blood gas, and bacterial cultures), examination costs (including lung function tests, electrocardiogram, and ultrasound), medical staff fees (including costs for physicians and nurses), bed or room fees, and other costs such as nebulization and oxygen therapy. Costs of dealing with multiple co-morbidities were excluded. All the patients had chest radiographs and CT scans. The frontal and lateral chest radiographic findings and CT scan images were reviewed and classified independently by two senior radiologists (LH Liang and QZ Zhao) and two senior physicians (YP Zhou and M Li) to ensure accuracy. Missing laboratory findings (most common in patients with less severe illness) were assumed to be normal \[[@CIT0019]\]. The principal investigator reviewed every form and medical record to ensure accuracy. The study was approved by our Institutional Review Board (Review Board of Guangdong Medical College). No informed consent was required because the data were already in existence.

Statistical analysis {#S20007}
--------------------

All statistical analyses were performed with Statistical Package for the Social Science for Windows version 13.0 (SPSS, Chicago, IL, USA). Categorical variables and continuous variables were reported as percentages and as the mean ± standard deviation (SD), respectively. The χ^2^ test, unpaired Student\'s *t*-test, univariate logistic regression and Spearman rank correlation were employed. A *p* value of \< 0.05 was considered statistically significant.

Results {#S0008}
=======

Baseline characteristics of patients {#S20009}
------------------------------------

Characteristics of the patients are presented in [Table I](#T0001){ref-type="table"}. Patients infected with *M. pneumoniae* were younger, more likely to be female, and more likely to have a less severe condition compared with such patients infected with other pathogens. *Mycoplasma pneumoniae* was an important causative organism of CAP in the current study, accounting for 30.2% of all cases. All patients underwent diagnostic tests for the detection of the etiologic agent of pneumonia, but the aetiologies were detected in only 21.7% of the patients infected with other pathogens. Hence, the data were not shown.

###### 

Baseline characteristics of the patients (mean ± SD, *n* = 1230)

  Variable                                                     *M. pneumoniae* pneumonia group   Other pneumonias group   *t* or χ^*2*^ value   Value of *p*
  ------------------------------------------------------------ --------------------------------- ------------------------ --------------------- --------------
  Age \[years\]                                                31.3 ±11.6                        50.4 ±22.4               15.702                \< 0.001
  Age ≥ 65 years \[%\]                                         2.2                               31.8                     132.151               \< 0.001
  Male sex \[%\]                                               39.8                              51.0                     13.717                \< 0.001
  Confusion \[%\]                                              0                                 2.1                      7.963                 0.005
  Body temperature \[°C\]                                      37.5 ±1.1                         37.5 ±1.1                0.281                 0.779
  Respiratory rate \[breaths/min\]                             19.7 ±2.3                         20.6 ±2.9                5.053                 \< 0.001
  Low blood pressure[\*](#TF0001){ref-type="table-fn"} \[%\]   15.1                              14.2                     0.171                 0.679
  WBC count \[10^9^/l\]                                        7.46 ±3.65                        8.83 ±4.42               5.353                 \< 0.001
  PaO~2~/FiO~2~ ≤ 250 mm Hg \[%\]                              0                                 3.6                      13.914                \< 0.001
  Serum BUN ≥ 7 mmol/l \[%\]                                   0                                 7.5                      29.413                \< 0.001
  Platelet count \[10^9^/l\]                                   245.69 ±96.52                     226.57 ±89.34            3.469                 0.001
  CURB-65 score: 0-1-2-3-4 \[%\]                               82.8-17.2-0-0-0                   53.8-35.4-9.4-1.1-0.2    107.118               \< 0.001
  Multilobar opacities, *n* (%)                                15.1 (56)                         29.3 (251)               29.295                \< 0.001
  Consolidation, *n* (%)                                       7.5 (28)                          12.1 (104)               5.838                 0.016

Systolic \< 90 mm Hg; or diastolic ≤ 60 mm Hg, WBC -- white blood cell, PaO~2~/FiO~2~ -- arterial oxygen pressure/fraction inspired oxygen, BUN -- blood urea nitrogen, CURB-65 -- confusion, urea, respiratory rate, blood pressure, and age

Mycoplasma pneumoniae-IgM titres {#S20010}
--------------------------------

The percentages of patients with *M. pneumoniae*-IgM titres of 1: 80, 1: 160, 1: 320, 1: 640, 1: 1280, 1: 2560 and 1: 5120 in acute phase sera in the *M. pneumoniae* pneumonia group were 26.9, 21.5, 11.8, 11.8, 20.4, 6.5 and 1.1, respectively. Patients with ground-glass opacification had higher *M. pneumoniae*-IgM titres compared with such patients with consolidation (1: 2.524 ±1: 0.521 vs. 1: 2.243 ±1: 0.414, *t* = 2.789, *p* = 0.006), but there was no significant difference in the titres between patients with a unilobar opacity and those with multilobar opacities (1: 2.515 ±1: 0.515 vs. 1: 2.436 ±1: 0.539, *t* = 1.024, *p* = 0.309). Ground-glass opacity showed a significant positive relationship with *M. pneumoniae*-IgM titres (rank correlation coefficient (*r* ~s~) = 0.141, *p* *=* 0.006). *Mycoplasma pneumonia* specific IgM titres in convalescent sera and *M. pneumonia* specific IgG titres were not shown.

Distribution of opacities {#S20011}
-------------------------

Distribution of opacities amongst the lobes is shown in [Figure 2](#F0002){ref-type="fig"}. A significant difference was observed between the two groups (χ^2^ = 110.824, *p* \< 0.001). Compared with other lobes, the left upper lobe appeared more susceptible to infection with *M. pneumoniae* than with other pathogens (χ^2^ = 4.437, *p* = 0.035).

![Distribution of opacities amongst the lobes](AMS-10-23423-g002){#F0002}

Radiological features according to demographic characteristics {#S20012}
--------------------------------------------------------------

Associations of lobar involvement and parenchymal opacification with patients' demographic characteristics are depicted in [Tables II](#T0002){ref-type="table"} and [III](#T0003){ref-type="table"}, respectively. Comparisons between the *M. pneumoniae* pneumonia group and the other pneumonias group are listed in columns, whereas comparisons between the subgroups are shown in rows. More increases in the risk of multilobar opacities were found among older patients than younger patients in both the *M. pneumoniae* pneumonia group and the other pneumonias group (odds ratio (OR), 1.065, 1.029; 95% confidence interval (CI), 1.041--1.089, 1.022--1.035; *p* \< 0.001, *p* \< 0.001; respectively). Older patients with *M. pneumoniae* pneumonia also showed a trend towards lower susceptibility to lobar pneumonia than younger patients (OR = 0.971; 95% CI: 0.932--1.011; *p* = 0.155), whereas older patients with other pneumonias had a decreased OR for lobar pneumonia compared with the younger patients (OR = 0.989; 95% CI: 0.980--0.997; *p* = 0.009). An increased OR for multilobar opacities was observed in male patients with *M. pneumoniae* pneumonia compared with the female patients (OR = 3.279; 95% CI: 1.812--5.934; *p* \< 0.001), whereas with other pathogens this was decreased (OR = 0.744; 95% CI: 0.570--0.973; *p* = 0.030).

###### 

Associations of lobar involvement with clinical and laboratory characteristics (mean ± SD, *n* = 1230)

  Variable                Group                       Multilobar opacities subgroup   Unilobar opacity subgroup   *t* or χ^*2*^ value   Value of *p*
  ----------------------- --------------------------- ------------------------------- --------------------------- --------------------- --------------
  Age \[years\]           *M. pneumoniae pneumonia*   39.9 ±15.2                      29.8 ±10.1                  6.349                 \< 0.001
  Other pneumonias        60.2 ±23.2                  46.3 ±20.8                      9.485                       \< 0.001              
  *t*                     6.298                       13.495                                                                            
  *p*                     \< 0.001                    \< 0.001                                                                          
  Male sex \[%\]          *M. pneumoniae pneumonia*   64.3                            35.4                        16.519                \< 0.001
  Other pneumonias        45.8                        53.1                            4.695                       0.030                 
  χ^2^                    6.509                       27.697                                                                            
  *p*                     0.011                       \< 0.001                                                                          
  CURB-65 score           *M. pneumoniae pneumonia*   0.29 ±0.46                      0.15 ±0.36                  2.459                 0.014
  Other pneumonias        0.90 ±0.85                  0.45 ±0.62                      9.523                       \< 0.001              
  *t*                     5.312                       8.076                                                                             
  *p*                     \< 0.001                    \< 0.001                                                                          
  SOFA score              *M. pneumoniae pneumonia*   0.43 ±0.0.74                    0.23 ±0.53                  2.459                 0.014
  Other pneumonias        1.20 ±1.59                  0.54 ±1.08                      7.762                       \< 0.001              
  *t*                     3.574                       4.915                                                                             
  *p*                     \< 0.001                    \< 0.001                                                                          
  Hospital LOS \[days\]   *M. pneumoniae pneumonia*   10.4 ±4.5                       9.1 ±3.0                    2.601                 0.010
  Other pneumonias        11.9 ±10.3                  9.4 ±4.4                        5.594                       \< 0.001              
  *t*                     1.126                       1.514                                                                             
  *p*                     0.261                       0.131                                                                             
  Costs \[\$\]            *M. pneumoniae pneumonia*   768.22 ±411.26                  623.47 ±270.69              3.375                 0.001
  Other pneumonias        1204.35 ±1323.26            703.60 ±443.74                  9.122                       \< 0.001              
  *t*                     2.366                       2.564                                                                             
  *p*                     0.019                       0.010                                                                             

CURB-65 -- confusion, urea, respiratory rate, blood pressure, and age, SOFA -- sequential organ failure assessment, LOS -- length of stay, \$ -- US dollars

###### 

Associations of parenchymal opacification with clinical and laboratory characteristics (mean ± SD, *n* = 1230)

  Variable                Group                       Lobar pneumonia subgroup   Bronchopneumonia subgroup   *t* or χ^*2*^ value   Value of *p*
  ----------------------- --------------------------- -------------------------- --------------------------- --------------------- --------------
  Age \[years\]           *M. pneumoniae pneumonia*   28.3 ±8.1                  31.6 ±11.8                  1.966                 0.057
  Other pneumonias        43.8 ±19.7                  51.1 ±22.6                 3.360                       0.001                 
  *t*                     4.340                       15.275                                                                       
  *p*                     \< 0.001                    \< 0.001                                                                     
  Male sex \[%\]          *M. pneumoniae pneumonia*   28.6                       40.7                        1.589                 0.207
  Other pneumonias        49.2                        51.2                       0.178                       0.915                 
  χ^2^                    3.934                       11.049                                                                       
  *p*                     0.047                       0.001                                                                        
  CURB-65 score           *M. pneumoniae pneumonia*   0.29 ±0.46                 0.16 ±0.37                  1.659                 0.098
  Other pneumonias        0.56 ±0.77                  0.58 ±0.72                 0.329                       0.742                 
  *t*                     2.057                       10.397                                                                       
  *p*                     0.041                       \< 0.001                                                                     
  SOFA score              *M. pneumoniae pneumonia*   0.14 ±0.36                 0.27 ±0.58                  1.119                 0.264
  Other pneumonias        0.64 ±1.34                  0.75 ±1.28                 0.823                       0.412                 
  *t*                     3.539                       6.741                                                                        
  *p*                     0.001                       \< 0.001                                                                     
  Hospital LOS \[days\]   *M. pneumoniae pneumonia*   14.1 ±4.4                  9.5 ±3.6                    5.409                 \< 0.001
  Other pneumonias        14.4 ±13.3                  9.6 ±5.2                   7.334                       \< 0.001              
  *t*                     0.100                       0.250                                                                        
  *p*                     0.920                       0.803                                                                        
  Costs \[\$\]            *M. pneumoniae pneumonia*   823.44 ±243.93             630.76 ±299.72              3.944                 \< 0.001
  Other pneumonias        1181.28 ±1311.15            808.57 ±749.44             4.579                       \< 0.001              
  *t*                     2.569                       4.001                                                                        
  *p*                     0.011                       \< 0.001                                                                     

CURB-65 -- confusion, urea, respiratory rate, blood pressure, and age, SOFA -- sequential organ failure assessment, LOS -- length of stay, \$ -- US dollars

Associations of lobar involvements with clinical and laboratory characteristics {#S20013}
-------------------------------------------------------------------------------

Associations of lobar involvements with clinical and laboratory characteristics are shown in [Table II](#T0002){ref-type="table"}. Multilobar opacities had significant positive relationships with CURB-65 scores in both the *M. pneumoniae* pneumonia group and the other pneumonias group (*r* ~s~ = 0.127, *r* ~s~ = 0.262; *p =* 0.014, *p* \< 0.001; respectively). Multilobar opacities were associated with longer hospital LOS in both the *M. pneumoniae* pneumonia group and the other pneumonias group (*r* ~s~ = 0.111, *r* ~s~ = 0.083; *p* = 0.033, *p* = 0.008; respectively), incurring significantly higher costs (*r* ~s~ = 0.119, *r* ~s~ = 0.201; *p* = 0.022, *p* \< 0.001; respectively).

Associations of parenchymal opacification with clinical and laboratory characteristics {#S20014}
--------------------------------------------------------------------------------------

Associations of parenchymal opacification with clinical and laboratory characteristics are shown in [Table III](#T0003){ref-type="table"}. Consolidation had significant positive relationships with hospital LOS in both the *M. pneumoniae* pneumonia group and the other pneumonias group (*r* ~s~ = 0.275, *r* ~s~ = 0.192; *p* \< 0.001, *p* \< 0.001; respectively), as it did with costs despite no association with the severity of the disease (*r* ~s~ = 0.200, *r* ~s~ = 0.151; *p* \< 0.001, *p* \< 0.001; respectively).

Discussion {#S0015}
==========

Our findings show that females were more susceptible to *M. pneumoniae* infection, that ground-glass opacification had a positive association with *M. pneumoniae*-IgM titres, that the left upper lobe was more susceptible to infection with *M. pneumoniae*, that older or male patients with *M. pneumoniae* pneumonia were more likely to show multilobar opacities, and that patients with *M. pneumoniae* pneumonia showing multilobar opacities or consolidation had a significantly longer hospital LOS and higher costs.

Radiographic manifestations of *M. pneumoniae* pneumonia can be extremely variable and mimic a wide variety of lung diseases. The inflammatory response elicited by *M. pneumoniae* causes interstitial mononuclear cell inflammation that may be manifested radiographically as diffuse, reticular infiltrates of bronchopneumonia in the perihilar regions or lower lobes, usually with a unilateral distribution, and hilar adenopathy \[[@CIT0004]\]. In the current study, the common radiographic features of *M. pneumoniae* pneumonia on chest radiographs and CT scans were ground-glass opacification, unilobar opacification, or lower lobe involvement as previously described by Mansel *et al*. \[[@CIT0011]\] and Reittner *et al*. \[[@CIT0020]\]. *Mycoplasma pneumoniae* is an extracellular pathogen, the survival of which depends on adherence to the respiratory epithelium, and this fixation to ciliary membranes is conducted primarily by interactive adhesion and accessory proteins. The major adhesion protein is P1 adhesin. Cytoadhesion protects *M. pneumoniae* from mucociliary clearance \[[@CIT0021]\]. Hydrogen peroxide and superoxide radicals synthesized by *M. pneumoniae* act in concert with endogenous toxic oxygen molecules generated by host cells to induce oxidative stress in the respiratory epithelium \[[@CIT0004]\]. Attachment of the microorganism to epithelial cilia is responsible for bronchial wall thickening \[[@CIT0021]\]. Therefore, this attachment might be envisaged to interpret higher frequency of the presentation of ground-glass opacification in *M. pneumoniae* pneumonia compared with other pneumonias and the association of ground-glass opacification with higher *M. pneumoniae*-IgM titres. Our finding that lobar involvement did not associate with IgM titres is not congruent with what Waites *et al*. \[[@CIT0004]\] observed (the cold agglutinin response often correlates directly with the severity of pulmonary involvement). On the basis of the current knowledge, we can envisage no definite mechanisms to account for the apparent increase in susceptibility of females to *M. pneumoniae* infection. As mycoplasma occurs in epidemic cycles, there may be local epidemiologic factors that may have played a role in the female preponderance to mycoplasma infection. Similarly, there is little information to determine the possible reasons why the left upper lobe was more susceptible to infection with *M. pneumoniae* than with other pathogens and it requires further epidemiological observations. Hence, further studies are warranted.

The frequency of consolidation in association with *M. pneumoniae* infection appears to vary greatly between studies. One study reported that consolidation was infrequent in adult patients in Japan \[[@CIT0010]\], Hsieh *et al*. \[[@CIT0012]\] reported a higher frequency of this pattern (38%) in paediatric patients in Taiwan, whereas Hosker *et al*. \[[@CIT0013]\] reported that 95% of paediatric patients presented with this pattern in Hong Kong and Defilippi *et al*. \[[@CIT0014]\] showed that consolidation was the commonest finding in children with infection due to *M. pneumoniae* in Genoa. Bilateral involvement may occur in about 20% of cases \[[@CIT0022]\], but it was observed in only 9.7% of the patients in the current study.

The factors determining disease manifestations and severity in *M. pneumoniae* infection are only partly understood. Few studies have attempted a clinical comparison of the effects of *M. pneumoniae* infection according to age. Youn *et al*. \[[@CIT0015]\] reported that paediatric patients with segmental/lobar pneumonia were older than those with bronchopneumonia in Korea. Defilippi *et al*. \[[@CIT0014]\] also found that the rate of chest radiographic consolidation was higher in older children with *M. pneumoniae* infection. There was a significantly increased OR for multilobar opacities in older adult patients and younger adult patients showed a trend toward susceptibility to lobar pneumonia in the current study. These may reflect the fact that the immune response and/or the mucociliary clearance of *M. pneumoniae* are less active in older adults and younger children, conferring a risk of more severe disease. On the basis of the above-mentioned rationale, it is difficult to interpret the positive association of multilobar opacities with male patients suffering from *M. pneumoniae* pneumonia in the current study. It warrants further study.

In the current study, the positive association of multilobar opacities, but not consolidation, with severity of the disease is consistent with the common understanding that the presentation of multilobar opacities is one of nine minor criteria for severe CAP \[[@CIT0001]\]. There have been few previous studies about the associations of radiological features with hospital LOS and costs in patients with pneumonia due to *M. pneumoniae*. The length of stay depends on the time needed to reach clinical stability, which is significantly influenced by the severity of disease \[[@CIT0023]\]. Bilateral or multilobar opacities on chest radiographs of low-risk CAP patients were not significantly associated with higher total costs \[[@CIT0008]\], but we found that multilobar opacities were positively associated with hospital LOS and costs in both groups, as was consolidation despite no association with the severity of the disease, which might have implications for the management of *M. pneumoniae* pneumonia and other pathogens pneumonia and health economics.

A few laboratory findings were inevitably missed due to retrospective data collection. This phenomenon is most common in patients with less severe illness. Missing values were assumed to be normal in the current study. This strategy is widely used in the clinical application of prediction rules and reflects the methods used in the original derivation and validation of the Pneumonia Severity Index \[[@CIT0019]\]. Even so, some of them might be abnormal. Therefore, the assumption might result in the alterations of statistical power and even statistical results and might give rise to misleading conclusions. Hence, further prospective validation of our findings is warranted.

Several limitations of this study deserve comment. First, the numbers of patients with consolidation or multilobar opacities were relatively small despite this being a cohort study. Had the number been larger, perhaps the results might have been more robust. The best method to detect acute *M. pneumoniae* infection is a polymerase chain reaction assay. Therefore, a few patients infected with *M. pneumoniae* might be excluded because of the absence of IgM antibodies in the early stage. It was not multicentre. A further weakness of this study was its retrospective design.

In conclusion, females were more susceptible to *M. pneumoniae* pneumonia. Ground-glass opacification was associated with higher *M. pneumoniae*-IgM titres. The left upper lobe might be more likely to be infected with *M. pneumoniae* compared with other pathogens. Older or male patients with *M. pneumoniae* pneumonia were more likely to show multilobar opacities. Multilobar opacities and consolidation were positively associated with hospital LOS and costs.
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